Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 2/2010

01.02.2010 | Original Article

Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma

verfasst von: Felisa Jiménez-Requena, Roberto C. Delgado-Bolton, Cristina Fernández-Pérez, Sanjiv S. Gambhir, Judy Schwimmer, José M. Pérez-Vázquez, José L. Carreras-Delgado

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of this study was to perform a systematic review of the literature to evaluate the accuracy of FDG-PET in staging and restaging of cutaneous melanoma.

Methods

Systematic methods were used to identify, select, and evaluate the methodologic quality of the studies as well as to summarize the overall findings of sensitivity and specificity. The search strategy consisted of identifying studies published between 2000 and 2006. Inclusion criteria were studies that evaluated the diagnostic performance of FDG-PET in staging/restaging of cutaneous melanoma. The results were compared and pooled with a meta-analysis published previously that included studies published until 1999. The meta-analysis included 95% confidence intervals (CI) of sensitivity, specificity, likelihood-ratio (LR), and diagnostic-odds-ratio (DOR).

Results

The quantitative meta-analysis included 24 studies that were analysed in two groups: eight studies were included only in the regional staging analysis (group I), 13 studies were included only in the detection of distant metastases analysis (group II), and three studies were included in both analyses. Compliance with the methodologic-quality criteria was acceptable. We analysed the results of data presented in patients, lesions, basins, lymph-nodes, areas, and scans. Regarding the performance of FDG-PET in the detection of metastases, the pooled studies presented homogeneity for the negative-LR (0.15; 95% CI, 0.10–0.22) when analyzing lesions. When analyzing scans, there was global homogeneity for specificity (0.86; 95% CI, 0.77–0.92), positive-LR (5.86; 95% CI, 3.64–9.43), and DOR (37.89; 95% CI, 15.80–90.86). The pooled studies presented heterogeneity for the other items analysed. Regarding the detection of regional metastases, when analyzing lymph-nodes there was global homogeneity for specificity (0.99; 95% CI, 0.97–0.99; P = 0.101). The meta-regression evidenced that the variable that most influenced the DOR of the different studies and that can explain the heterogeneity was the year of publication; this may be related to the evolution of PET technology and an improvement of sensitivity/specificity.

Conclusion

FDG-PET is not useful in the evaluation of regional metastases, as it does not detect microscopic disease. However, FDG-PET could be useful in the detection of distant metastases, and could suggest its utility in the management of patients with cutaneous melanoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Melanoma. National Comprehensive Cancer Care Network: Clinical Practice Guidelines in Oncology-v1. 2005. Melanoma. National Comprehensive Cancer Care Network: Clinical Practice Guidelines in Oncology-v1. 2005.
2.
Zurück zum Zitat ACS. American Cancer Society: Cancer Factors and Figures 2006. Atlanta, Ga: American Cancer Society 2006. Also available online. Last accessed August 7, 2006. ACS. American Cancer Society: Cancer Factors and Figures 2006. Atlanta, Ga: American Cancer Society 2006. Also available online. Last accessed August 7, 2006.
3.
Zurück zum Zitat AJCC. Melanoma of the skin. In: American Joint Committee on Cancer: AJCC cancer staging manual. 6th ed. New York: Springer; 2002. p. 209–20. AJCC. Melanoma of the skin. In: American Joint Committee on Cancer: AJCC cancer staging manual. 6th ed. New York: Springer; 2002. p. 209–20.
4.
Zurück zum Zitat Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–91.CrossRefPubMed Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–91.CrossRefPubMed
5.
Zurück zum Zitat Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.PubMed Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.PubMed
6.
Zurück zum Zitat Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530–42.CrossRefPubMed Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530–42.CrossRefPubMed
7.
Zurück zum Zitat Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med. 2000;44:153–67.PubMed Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med. 2000;44:153–67.PubMed
8.
Zurück zum Zitat Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127:380–7.PubMed Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127:380–7.PubMed
9.
Zurück zum Zitat Paquet P, Henry F, Belhocine T, et al. An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging. Dermatology. 2000;200:167–9.CrossRefPubMed Paquet P, Henry F, Belhocine T, et al. An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging. Dermatology. 2000;200:167–9.CrossRefPubMed
10.
Zurück zum Zitat Klein M, Freedman N, Lotem M, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study. Nuklearmedizin. 2000;39:56–61.PubMed Klein M, Freedman N, Lotem M, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study. Nuklearmedizin. 2000;39:56–61.PubMed
11.
Zurück zum Zitat Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000;41:1491–4.PubMed Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000;41:1491–4.PubMed
12.
Zurück zum Zitat Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 2000;27:70–5.CrossRefPubMed Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 2000;27:70–5.CrossRefPubMed
13.
Zurück zum Zitat Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019–25.CrossRefPubMed Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019–25.CrossRefPubMed
14.
Zurück zum Zitat Acland KM, O’Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol. 2000;42:606–11.CrossRefPubMed Acland KM, O’Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol. 2000;42:606–11.CrossRefPubMed
15.
Zurück zum Zitat Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674–8.PubMed Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674–8.PubMed
16.
Zurück zum Zitat Reinhardt MJ, Kensy J, Frohmann JP, et al. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin. 2002;41:143–7.PubMed Reinhardt MJ, Kensy J, Frohmann JP, et al. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin. 2002;41:143–7.PubMed
17.
Zurück zum Zitat Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res. 2002;12:479–90.CrossRefPubMed Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res. 2002;12:479–90.CrossRefPubMed
18.
Zurück zum Zitat Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol. 2002;9:646–53.CrossRefPubMed Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol. 2002;9:646–53.CrossRefPubMed
19.
Zurück zum Zitat Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist. 2002;7:271–8.CrossRefPubMed Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist. 2002;7:271–8.CrossRefPubMed
20.
Zurück zum Zitat Longo MI, Lazaro P, Bueno C, Carreras JL, Montz R. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg. 2003;29:245–8.CrossRefPubMed Longo MI, Lazaro P, Bueno C, Carreras JL, Montz R. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg. 2003;29:245–8.CrossRefPubMed
21.
Zurück zum Zitat Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004;14:141–5.CrossRefPubMed Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004;14:141–5.CrossRefPubMed
22.
Zurück zum Zitat Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol. 2004;150:677–86.CrossRefPubMed Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol. 2004;150:677–86.CrossRefPubMed
23.
Zurück zum Zitat Finkelstein SE, Carrasquillo JA, Hoffman JM, et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol. 2004;11:731–8.CrossRefPubMed Finkelstein SE, Carrasquillo JA, Hoffman JM, et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol. 2004;11:731–8.CrossRefPubMed
24.
Zurück zum Zitat Vereecken P, Laporte M, Petein M, Steels E, Heenen M. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol. 2005;19:66–73.CrossRefPubMed Vereecken P, Laporte M, Petein M, Steels E, Heenen M. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol. 2005;19:66–73.CrossRefPubMed
25.
Zurück zum Zitat Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104:570–9.CrossRefPubMed Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104:570–9.CrossRefPubMed
26.
Zurück zum Zitat Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34:1420–7.PubMed Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34:1420–7.PubMed
27.
Zurück zum Zitat Boni R, Boni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol. 1995;132:556–62.PubMedCrossRef Boni R, Boni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol. 1995;132:556–62.PubMedCrossRef
28.
Zurück zum Zitat Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;195:705–9.PubMed Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;195:705–9.PubMed
29.
Zurück zum Zitat Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol. 1995;131:1394–8.CrossRefPubMed Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol. 1995;131:1394–8.CrossRefPubMed
30.
Zurück zum Zitat Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737–43.CrossRefPubMed Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737–43.CrossRefPubMed
31.
Zurück zum Zitat Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325–9.CrossRefPubMed Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325–9.CrossRefPubMed
32.
Zurück zum Zitat Wagner JD, Schauwecker D, Hutchins G, Coleman JJ 3rd. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol. 1997;64:181–9.CrossRefPubMed Wagner JD, Schauwecker D, Hutchins G, Coleman JJ 3rd. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol. 1997;64:181–9.CrossRefPubMed
33.
Zurück zum Zitat Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg. 1998;187:191–7.CrossRefPubMed Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg. 1998;187:191–7.CrossRefPubMed
34.
Zurück zum Zitat Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227:764–9.CrossRefPubMed Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227:764–9.CrossRefPubMed
35.
Zurück zum Zitat Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16:1770–6.PubMed Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16:1770–6.PubMed
36.
Zurück zum Zitat Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82:1664–71.CrossRefPubMed Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82:1664–71.CrossRefPubMed
37.
Zurück zum Zitat Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999;17:1508–15.PubMed Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999;17:1508–15.PubMed
38.
Zurück zum Zitat Dietlein M, Krug B, Groth W, et al. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun. 1999;20:255–61.CrossRefPubMed Dietlein M, Krug B, Groth W, et al. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun. 1999;20:255–61.CrossRefPubMed
39.
Zurück zum Zitat Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–89.PubMed Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–89.PubMed
40.
Zurück zum Zitat Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914–24.CrossRefPubMed Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914–24.CrossRefPubMed
41.
Zurück zum Zitat Delgado-Bolton RC, Fernández-Pérez C, González-Maté A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med. 2003;44:1301–14.PubMed Delgado-Bolton RC, Fernández-Pérez C, González-Maté A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med. 2003;44:1301–14.PubMed
42.
Zurück zum Zitat Kent DL, Larson EB. Disease, level of impact, and quality of research methods. Three dimensions of clinical efficacy assessment applied to magnetic resonance imaging. Invest Radiol. 1992;27:245–54.CrossRefPubMed Kent DL, Larson EB. Disease, level of impact, and quality of research methods. Three dimensions of clinical efficacy assessment applied to magnetic resonance imaging. Invest Radiol. 1992;27:245–54.CrossRefPubMed
43.
Zurück zum Zitat Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88–94.CrossRefPubMed Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88–94.CrossRefPubMed
44.
Zurück zum Zitat Thornbury JR, Kido DK, Mushlin AI, Phelps CE, Mooney C, Fryback DG. Increasing the scientific quality of clinical efficacy studies of magnetic resonance imaging. Invest Radiol. 1991;26:829–35.CrossRefPubMed Thornbury JR, Kido DK, Mushlin AI, Phelps CE, Mooney C, Fryback DG. Increasing the scientific quality of clinical efficacy studies of magnetic resonance imaging. Invest Radiol. 1991;26:829–35.CrossRefPubMed
45.
Zurück zum Zitat Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–316.PubMed Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–316.PubMed
46.
Zurück zum Zitat Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.CrossRefPubMed Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.CrossRefPubMed
47.
Zurück zum Zitat Gregoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol. 1995;48:159–63.CrossRefPubMed Gregoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol. 1995;48:159–63.CrossRefPubMed
48.
Zurück zum Zitat Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet. 1996;347:363–6.CrossRefPubMed Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet. 1996;347:363–6.CrossRefPubMed
Metadaten
Titel
Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma
verfasst von
Felisa Jiménez-Requena
Roberto C. Delgado-Bolton
Cristina Fernández-Pérez
Sanjiv S. Gambhir
Judy Schwimmer
José M. Pérez-Vázquez
José L. Carreras-Delgado
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1224-8

Weitere Artikel der Ausgabe 2/2010

European Journal of Nuclear Medicine and Molecular Imaging 2/2010 Zur Ausgabe